Related Experiment Videos
Relationship between transforming growth factor beta1 and progression of hypertensive renal disease
R Scaglione1, C Argano, G Parrinello
1University of Palermo, Italy. rosarioscaglione@yahoo.it
Insights
Circulating transforming growth factor beta1 (TGFbeta1) is elevated in hypertensive kidney disease patients with higher urinary albumin excretion. Higher TGFbeta1 levels correlate with increased renal disease severity and left ventricular hypertrophy.
Area of Science:
- Nephrology
- Cardiology
- Biochemistry
Background:
- Essential hypertension is a leading cause of chronic kidney disease.
- Urinary albumin excretion (UAE) is a marker of kidney damage.
- Transforming growth factor beta1 (TGFbeta1) plays a role in fibrotic processes.
Purpose of the Study:
- To investigate the role of circulating TGFbeta1 in the progression of hypertensive renal disease.
- To correlate TGFbeta1 levels with UAE and cardiac parameters in hypertensive patients.
Main Methods:
- Fifty hypertensive outpatients were grouped by UAE: normoalbuminuric (
- Circulating TGFbeta1, UAE, BUN, creatinine, and echocardiographic parameters (including left ventricular mass and interventricular septum diastolic diameter - IVSTd) were measured.
- Statistical analysis was performed to compare groups and assess correlations.
Main Results:
- TGFbeta1 levels were significantly higher in microalbuminuric and proteinuric groups compared to normoalbuminuric.
- TGFbeta1 levels were also significantly higher in the proteinuric group than the microalbuminuric group.
- IVSTd was significantly higher in both microalbuminuric and proteinuric groups compared to normoalbuminuric.
- TGFbeta1 correlated directly with UAE (P < 0.0001) but not with BMI, left ventricular mass, or mean blood pressure.
Conclusions:
- Elevated circulating TGFbeta1 is associated with increased severity of hypertensive renal disease.
- TGFbeta1 may serve as a valuable biomarker for assessing hypertensive renal disease progression.
- Further research is needed to explore TGFbeta1 inhibition for treating end-stage renal disease in hypertensive patients.
Abstract:
In this study the role of circulating transforming growth factor beta1 (TGFbeta1) on progression of renal hypertensive disease has been investigated. Fifty consecutive outpatients with essential hypertension were enrolled and divided into three groups, according to their urinary albumin excretion (UAE). Group A comprised 10 hypertensives with UAE